DISCARD Trial: Linear vs Hyperbolic Antidepressant Tapering Protocol

This protocol describes the first randomised head-to-head comparison of linear versus hyperbolic antidepressant tapering, addressing a longstanding evidence gap directly relevant to deprescribing practice.

antidepressantsSSRISNRItricyclic antidepressantvortioxetinedeprescribinghyperbolic taperinglinear taperingdepressionwithdrawal symptomsdiscontinuationRCT protocolDISCARDpharmacovigilance Psychiatry / Psychopharmacology

Background Information

Exploring safer ways to stop antidepressants in remitted depression.

Antidepressant overprescribing can lead to unnecessary long-term use and withdrawal symptoms, making safe discontinuation strategies essential. This trial compares linear versus hyperbolic tapering strategies for discontinuing antidepressants in adults with remitted depressive disorders over a 36-week period. The study addresses gaps in evidence by examining the effectiveness and safety of tapering strategies, crucial for optimizing patient outcomes during antidepressant discontinuation. This trial evaluates crucial strategies for safely tapering antidepressants, addressing adverse effects and withdrawal symptoms.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Ostuzzi G, Gastaldon C, Zaccoletti D, Bartoli F, Belnome G, Carrà G, Cavallotti S, Cristea I, D'Agostino A, De Fazio P, de Filippis R, Gottardi C, Novara C, Papola D, Riboldi I, Tedeschi F, Amaddeo F, Barbui C

Citation: Ostuzzi G, Gastaldon C, Zaccoletti D, et al. Safe discontinuation of antidepressants in individuals with clinically remitted depressive disorders: study protocol for a randomised controlled trial. BMJ open. 2026;16(7):e119492. doi:10.1136/bmjopen-2026-119492

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →